hy-p0086 Search Results


factor human crh  (MedChemExpress)
92
MedChemExpress factor human crh
Bexarotene treatment reduces POMC transcription and ACTH secretion in AtT‐20 cells. A, Changes in POMC and TR4 mRNA after treatment with 0, 5 and 10 µmol/L bexarotene for 12 h were assessed by qPCR; B, Protein levels of POMC and TR4 after treatment with 0, 5 and 10 µmol/L bexarotene for 24 h were assessed by Western blot analysis. C, Cells were transfected with a POMC promoter‐luciferase reporter and pRL‐TK(Δ238); after 18 h, cells were treated with 0, 5 or 10 µmol/L bexarotene for 24 h, and luciferase activities were measured and presented as the fold change compared the control; D, AtT‐20 cells were treated for 24 h with 0, 5 or 10 µmol/L bexarotene, 40 µmol/L MEK‐162, 100 nmol/L <t>CRH,</t> 100 nmol/L DEX, or their combinations as indicated. ACTH levels were measured in the supernatants from AtT‐20 cells through ECLIA. Results are expressed as the percentages of each control. Data are the means * SEM of three independent experiments. * P ˂ .05, ** P ˂ .01 except in Figure * P ˂ .01, compared with the basal values, ** P ˂ .01 compared with CRH stimulation, *** P ˂ .01 compared with DEX suppression. One‐way ANOVA and two‐way ANOVA were used to test differences for statistical significance
Factor Human Crh, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-p0086/Corticotropin-releasing+factor/pmc07933964-59-1-7
Average 92 stars, based on 1 article reviews
factor human crh - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

Image Search Results


Bexarotene treatment reduces POMC transcription and ACTH secretion in AtT‐20 cells. A, Changes in POMC and TR4 mRNA after treatment with 0, 5 and 10 µmol/L bexarotene for 12 h were assessed by qPCR; B, Protein levels of POMC and TR4 after treatment with 0, 5 and 10 µmol/L bexarotene for 24 h were assessed by Western blot analysis. C, Cells were transfected with a POMC promoter‐luciferase reporter and pRL‐TK(Δ238); after 18 h, cells were treated with 0, 5 or 10 µmol/L bexarotene for 24 h, and luciferase activities were measured and presented as the fold change compared the control; D, AtT‐20 cells were treated for 24 h with 0, 5 or 10 µmol/L bexarotene, 40 µmol/L MEK‐162, 100 nmol/L CRH, 100 nmol/L DEX, or their combinations as indicated. ACTH levels were measured in the supernatants from AtT‐20 cells through ECLIA. Results are expressed as the percentages of each control. Data are the means * SEM of three independent experiments. * P ˂ .05, ** P ˂ .01 except in Figure * P ˂ .01, compared with the basal values, ** P ˂ .01 compared with CRH stimulation, *** P ˂ .01 compared with DEX suppression. One‐way ANOVA and two‐way ANOVA were used to test differences for statistical significance

Journal: Journal of Cellular and Molecular Medicine

Article Title: Targeting the TR4 nuclear receptor with antagonist bexarotene can suppress the proopiomelanocortin signalling in AtT‐20 cells

doi: 10.1111/jcmm.16074

Figure Lengend Snippet: Bexarotene treatment reduces POMC transcription and ACTH secretion in AtT‐20 cells. A, Changes in POMC and TR4 mRNA after treatment with 0, 5 and 10 µmol/L bexarotene for 12 h were assessed by qPCR; B, Protein levels of POMC and TR4 after treatment with 0, 5 and 10 µmol/L bexarotene for 24 h were assessed by Western blot analysis. C, Cells were transfected with a POMC promoter‐luciferase reporter and pRL‐TK(Δ238); after 18 h, cells were treated with 0, 5 or 10 µmol/L bexarotene for 24 h, and luciferase activities were measured and presented as the fold change compared the control; D, AtT‐20 cells were treated for 24 h with 0, 5 or 10 µmol/L bexarotene, 40 µmol/L MEK‐162, 100 nmol/L CRH, 100 nmol/L DEX, or their combinations as indicated. ACTH levels were measured in the supernatants from AtT‐20 cells through ECLIA. Results are expressed as the percentages of each control. Data are the means * SEM of three independent experiments. * P ˂ .05, ** P ˂ .01 except in Figure * P ˂ .01, compared with the basal values, ** P ˂ .01 compared with CRH stimulation, *** P ˂ .01 compared with DEX suppression. One‐way ANOVA and two‐way ANOVA were used to test differences for statistical significance

Article Snippet: Corticotropin‐releasing factor human (CRH) was obtained from MCE and stored at −80°C.

Techniques: Western Blot, Transfection, Luciferase, Control